Safety and effectiveness of pirfenidone combined with carboplatin-based chemotherapy in patients with idiopathic pulmonary fibrosis and non-small cell lung cancer: A retrospective cohort study.
Yuji YamamotoYukihiro YanoTomoki KugeFukuko OkabeMikako IshijimaTakeshi UenamiMasaki KanazuYuki AkazawaToshihiko YamaguchiMasahide MoriPublished in: Thoracic cancer (2020)
SIGNIFICANT FINDINGS OF THE STUDY: No patients with IPF and NSCLC who received pirfenidone in combination with first-line carboplatin-based chemotherapy or late-line ICIs developed acute IPF exacerbations. What this study adds Pirfenidone might have a prophylactic effect against chemotherapy-associated AE-IPF.
Keyphrases
- idiopathic pulmonary fibrosis
- interstitial lung disease
- locally advanced
- randomized controlled trial
- small cell lung cancer
- chronic obstructive pulmonary disease
- phase ii study
- systematic review
- cystic fibrosis
- squamous cell carcinoma
- liver failure
- clinical trial
- radiation therapy
- chemotherapy induced
- open label
- study protocol
- pulmonary fibrosis